Good second quarter for Bausch and Lomb:
This article was originally published in Clinica
Second-quarter revenues at Bausch & Lomb's medical business were up 12% compared with the previous year. No figures were provided. The medical division includes Miracle-Ear hearing aids, up 8%, dental implants, up 15%, as well as contact lenses which rose 14% and prescription pharmaceuticals, up 8%. The medical business is part of Bausch & Lomb's healthcare segment where revenues increased 4% to $369 million in the second quarter.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.